2016 Annual Meeting | Cerebrovascular Disease III: Acute Ischemic Stroke

Date Monday 04/18/16

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Philip B. Gorelick, MD, MPH, FAAN

Topic(s)

Learning Objectives Participants should be able to better understand diagnosis and management of acute ischemic stroke in everyday practice in relation to intravenous tPA administration; how eligibility criteria for tPA administration have changed over the years; what recent guidelines recommend; how time to administration of tPA is being reduced by pre-hospital and other system changes; proper application of neurothrombectomy in everyday practice; and new guidelines for application of neurothrombectomy.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic

Event Timeline
03:30 PM - 04:15 PM		tPA Administration for Acute Ischemic Stroke: A 20-Year Perspective James C. Grotta, MD, FAAN
04:15 PM - 04:30 PM		Questions and Answers James C. Grotta, MD, FAAN
04:30 PM - 05:15 PM		Neurothrombectomy for Acute Ischemic Stroke Andrew M. Demchuk, MD
05:15 PM - 05:30 PM		Questions and Answers Andrew M. Demchuk, MD

Faculty Disclosures
Philip B. Gorelick, MD, MPH, FAAN	Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Thorek Memorial Hospital. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Thorek Memorial Hospital.
James C. Grotta, MD, FAAN	Dr. Grotta has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Frazer Ltd. Dr. Grotta has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Haemonetics. Dr. Grotta has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acticor. Dr. Grotta has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prolong Pharma. Dr. Grotta has received publishing royalties from a publication relating to health care. Dr. Grotta has received publishing royalties from a publication relating to health care.
Andrew M. Demchuk, MD	Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lumosa. Dr. Demchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer/BMS. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Demchuk has received stock or an ownership interest from Circle NVI. Dr. Demchuk has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��